Leech Therapy for Knee Osteoarthritis — The Landmark RCT

First RCT showing leech therapy superior to topical diclofenac for OA pain

Clinical LiteratureMichalsen et al. (2003)— Annals of Internal MedicineDOI →

Why This Matters for Hirudotherapy

Published in Annals of Internal Medicine, this 51-patient randomized trial compared a single leech treatment with topical diclofenac in knee osteoarthritis. The authors concluded that leech therapy helps relieve symptoms and that its potential for treating osteoarthritis and the pharmacologic properties of leech saliva remain to be clarified.

Clinical Evidence — Not FDA-Evaluated

Investigational use. Leech therapy for osteoarthritis is not FDA-cleared. This review summarizes the clinical trial evidence for educational purposes.

Last Updated: May 27, 2026Reviewed by: Andrei Dokukin, MD

Single-RCT analysis: knee OAPending FDA OA indication

Background and significance

Before this trial, evidence for leech therapy in knee osteoarthritis came from preliminary data, including a 2002 observational, controlled, nonrandomized pilot study of 16 inpatients (Michalsen et al., Altern Ther Health Med 2002; PMID 12233807). Michalsen et al. then conducted a randomized, controlled trial in 51 patients, published in the Annals of Internal Medicine in 2003.[R1]

Study design

Intervention

A single treatment with 4 to 6 locally applied leeches (leech therapy group, n = 24).

Control

A 28-day topical diclofenac regimen (control group, n = 27).

N = 51

Randomized patients

Knee OA

Symptomatic, confirmed

91 days

Follow-up period

Data from Michalsen et al. (2003).[R1]

Primary outcomes

The primary end point was pain at day 7; secondary comparisons covered function, stiffness, total symptoms and quality of life at days 3, 7, 28 and 91:

Measure	Baseline	Day 7	Change
Pain (primary end point)	53.5 ± 13.7	19.3 ± 12.2	−34.2 points (−64%)

Between-group difference in pain at day 7: -23.9 (95% CI -32.8 to -15.1; P < 0.001). The difference between group pain scores was no longer significant after day 7; differences for function, stiffness and total symptoms remained significant in favor of leech therapy until the end of the study.[R1]

Duration of effect

After a single treatment, the difference in pain between leech therapy and diclofenac was no longer significant after day 7, but differences for function, stiffness and total symptoms remained significant in favor of leech therapy until the end of the study (day 91) and for quality of life until day 28. The study followed patients to day 91; the authors state that the pharmacologic properties of leech saliva remain to be clarified.[R1]

Safety profile

In the full trial report, local itching occurred in 17 of 24 leech-treated patients (mean duration 4 days); no serious adverse effects and no infections were reported (Michalsen et al. 2003).[R1]

Subsequent confirmatory trials

Subsequent trials and a meta-analysis of leech therapy in knee osteoarthritis include:

Study	N	Design	Result
Andereya et al. 2008	113	Sham-controlled (knee OA)	KOOS/WOMAC/VAS improved in all groups; significant in the leech-treated groups
Lauche et al. 2014	3 RCTs + 1 CCT (237 patients)	Meta-analysis	Moderate to strong evidence for reduced pain, functional impairment and stiffness in knee OA; further high-quality RCTs required

Proposed mechanisms

The prolonged effect of a single leech application suggests multiple overlapping mechanisms:

Anti-inflammatory

Leech secretions contain protease inhibitors such as bdellins and eglins that are proposed to have anti-inflammatory effects; hyaluronidase is described as degrading extracellular matrix to help bioactive molecules spread, not as an anti-inflammatory agent. Effects on joint inflammation in osteoarthritis have not been demonstrated.

Microcirculatory

Local blood flow improvement through anticoagulant and vasodilatory effects may reduce tissue hypoxia and promote healing in the peri-articular tissues.

Analgesic

Leeches are believed to exert analgesic and anti-inflammatory effects, but no analgesic molecule has yet been isolated from leech secretions; indirect mechanisms (e.g. inhibition of the kinin-kallikrein system by antistasin, a factor Xa inhibitor from Haementeria officinalis) have been proposed.

Regulatory status

Leech therapy for osteoarthritis is not FDA-cleared. The FDA 510(k) clearance for medicinal leeches is limited to relief of venous congestion in microsurgical procedures. Use for OA is considered investigational/off-label in the United States. Clinical decisions should be made within appropriate institutional and regulatory frameworks.

Related entries: condition/knee-osteoarthritis (Tier B) · evidence summary · /how-evidence-graded.

References

[R1]
Effectiveness of Leech Therapy in Osteoarthritis of the Knee: A Randomized, Controlled Trial
Annals of Internal Medicine(2003)https://doi.org/10.7326/0003-4819-139-9-200311040-00006
Primary source. First randomized controlled trial of leech therapy for OA.
[R2]
Effectiveness of Leech Therapy in Chronic Lateral Epicondylitis: A Randomized Controlled Trial
Clinical Journal of Pain(2011)https://doi.org/10.1097/AJP.0b013e318208c95b
Subsequent RCT (Bäcker M, ..., Michalsen A; 40 patients) of a single leech treatment vs a 30-day course of topical diclofenac in chronic lateral epicondylitis. PMID 21368667.
[R3]
A Systematic Review and Meta-Analysis of Medical Leech Therapy for Osteoarthritis of the Knee
Clinical Journal of Pain(2014)https://doi.org/10.1097/AJP.0b013e31828440ce
Lauche et al. systematic review and meta-analysis of 3 RCTs and 1 nonrandomized controlled clinical trial (237 patients): moderate to strong evidence for reduced pain, functional impairment and stiffness in knee OA; further high-quality RCTs required.

← All research articles